One of the most abundant components in human milk is formed by oligosaccharides, which are poorly digested by the infant. The oligosaccharide composition of breast milk varies between mothers, and is dependent on maternal secretor (FUT2) genotype. Secretor mothers produce milk containing α1-2 fucosylated human milk oligosaccharides, which are absent in the milk of non-secretor mothers. Several strains of bacteria in the infant gut have the capacity to utilise human milk oligosaccharides (HMOs). Here we investigate the differences in infant gut microbiota composition between secretor (N = 76) and non-secretor (N = 15) mothers, taking into account birth mode. In the vaginally born infants, maternal secretor status was not associated with microbiota composition. In the caesarean-born, however, many of the caesarean-associated microbiota patterns were more pronounced among the infants of non-secretor mothers compared to those of secretor mothers. Particularly bifidobacteria were strongly depleted and enterococci increased among the caesarean-born infants of non-secretor mothers. Furthermore, Akkermansia was increased in the section-born infants of secretor mothers, supporting the suggestion that this organism may degrade HMOs. The results indicate that maternal secretor status may be particularly influential in infants with compromised microbiota development, and that these infants could benefit from corrective supplementation.
Infants are adapted to obtaining all of their nutrition from human milk during the first months of life. In addition to nutrients for the infant, breast milk contains a diverse mixture of complex oligosaccharides, termed human milk oligosaccharides (HMOs), at an abundance of approximately 10 g/l1. These oligosaccharides are poorly digested by the infant, but are favoured growth substrates for intestinal bacteria that have the appropriate enzymatic degradation capacity. The oligosaccharide composition and abundance in breast milk is dependent on maternal genetics, particularly the FUT2 gene, which encodes an enzyme responsible for the addition of fucose at the α1-2 position on a backbone of abundant glycans containing galactose1. The breast milk of mothers with a functional FUT2 allele, the so-called secretors, contains a large amount of α1-2 fucosylated HMOs, most abundantly 2′fucosyllactose (2′FL), and in lesser amounts lactodifucotetraose (LDFT), lacto-N-difucohexaose I (LNDFH I) and lacto-N-fucopentaose I (LNFP I)1,2. The breast milk of non-secretor mothers lacks or has only traces of these α1-2 fucosylated oligosaccharides, thus containing a lower total amount of HMOs1,2, although this lack may be partly compensated by higher abundances of lacto-N-tetraose (LNT), LNFP II, and III and LNDFH II1. The abundance of 2′FL in breast milk has been shown to be a reliable indicator of secretor status2.
Maternal secretor phenotype has been recently linked with reduced risk of atopic dermatitis in a cohort of caesarean-born infants3, and individual HMOs were related to reduced risk of cow’s milk allergy4. Although HMOs are reported to have immunomodulatory effects, these are mainly restricted to sialylated HMOs5,6, which are not dependent on maternal secretor status. Although some fucosylated HMOs like 2′ FL can bind the dendritic cell receptor DC-SIGN7 and modulate inflammation via CD148, it is not known whether this leads to direct allergy-related immunological effects.
One likely manner in which maternal secretor status influences the infant’s immune system development is via the gut microbiota. The α1-2 fucosylated oligosaccharides are degraded by enzymes of the glycosyl hydrolase family 95, possessed by strains of bifidobacteria commonly observed in infants (strains of B. longum infants, B. bifidum, B. breve) as well as Bacteroides spp.9,10,11,12,13. The abundance of these bacteria is associated with birth mode, being commonly reduced in caesarean-born infants14. We therefore hypothesise that the impact of maternal secretor status on infant microbiota may depend on birth mode. Here we investigate the differences in infant gut microbiota composition between secretor and non-secretor mothers, taking into account birth mode.
We analysed the association between microbiota composition in infants and the presence of 2′FL in maternal breast milk (secretors), stratifying the infants by birth mode. The stratification of the samples into groups based on birth mode and the presence of 2′FL in maternal breast milk explained 19% the inter-individual variation in phylum-level microbiota composition (Fig. 1A). The maternal secretor phenotype was not associated with the overall microbiota composition among the vaginally born infants (Fig. 1A; permutational multivariate ANOVA, p = 0.98). Among the caesarean born infants, however, the maternal secretor phenotype was associated with an overall shift in the total microbiota composition, which was close to statistical significance (Fig. 1A, p = 0.07). The caesarean-born infants of secretor mothers had a more modest deviation in microbiota composition, compared to those of non-secretor mothers (Fig. 1A,B).
Among the vaginally born infants, there were no significant differences between infants of secretor and non-secretor mothers in the relative abundance of bacterial taxa, after adjustment for full or partial breastfeeding and at the FDR-corrected p-value level 0.1 (Supplementary Table 1). All caesarean-born infants had significant reductions in the relative abundance of Bacteroidetes (non-secretors, 500-fold reduced, p < 0.0001; secretors, 200-fold reduced, p < 0.0001, mainly genera Bacteroides and Parabacteroides) and an increase of Firmicutes (non-secretors, 3.8-fold, p = 0.002; secretors 2.6-fold, p = 0.0002, mainly Bacilli) in their gut microbiota, compared to the vaginally born infants of secretor mothers. The magnitude of these effects was higher in the infants of non-secretor mothers (Supplementary Table 1, Fig. 2), who also showed a significant reduction in Actinobacteria (3.7-fold, p = 0.001, mainly Bifidobacterium) and a 13-fold increase in Enterococcus (p = 0.003). The reduction in bifidobacteria was largely due to the absence of Bifidobacterium bifidum and B. breve (Fig. 3A), while the increase in enterococci was attributable to a bloom of Enterococcus lactis and two uncultured Enterococcus species; Enterococcus faecium levels were comparable (Fig. 3B). In addition, there was a non-significant trend towards higher Proteobacteria abundance in the caesarean-born infants of non-secretor mothers (Fig. 2, Supplementary Table 1), and the caesarean-born infants of secretor mothers had significantly increased relative abundance (approximately ten-fold) of Verrucomicrobia (Akkermansia muciniphila, Fig. 2, Supplementary Table 1).
In addition to the differences in relative abundance, we observed differences in the sequence-level diversity of several genera, indicating variation in the diversity of species and strains. The diversity (number of unique sequences assigned to the particular genus) of bifidobacteria and bacteroides was significantly reduced in the caesarean-born infants, especially clearly in the infants of non-secretor mothers (Fig. 4A,B), while the diversity of enterococci and Lachnospiraceae incertae sedis showed the opposite pattern (Fig. 4C,D).
Our results indicate that infants of non-secretor mothers are particularly vulnerable to the effects of caesarean section on the early microbiota development. The combination of caesarean birth and lack of milk 2′FL appear to profoundly alter the infant’s microbiota.
A few previous studies have investigated the association between maternal secretor status and infant microbiota. Low abundance of bifidobacteria has been reported in infants of non-secretor mothers15, corresponding to our observations among the caesarean-born infants, but these associations are not universal. Wang et al. report a negative correlation between 2′FL and LDFT in breast milk and the relative abundance of bifidobacteria in infant faeces, but a positive correlation with Bacteroides16. This suggests that the principal degraders of fucosylated HMOs may vary between cohorts, depending on the composition of the microbiota. In our cohort, maternal secretor status had no impact on the microbiota composition among the vaginally born infants, indicating that maternal secretor status may be an important factor mainly among infants with otherwise compromised microbiota development. Curiously, the overall abundance of bifidobacteria in the cohort of Lewis et al. (2015) was similar to that of the caesarean-born infants in our cohort. The HMO degradation capacity of bifidobacteria is not restricted to the α1-2 fucosylated HMOs17,18. Perhaps a high diversity of bifidobacteria ensures that the community is able to adapt to the available HMOs, reducing their dependence on specific HMO types.
In the caesarean-born infants, the only taxon appearing to benefit from the lack of α1-2 fucosylated HMOs was Enterococcus (member of Lactobacillales), particularly Enterococcus lactis. E. lactis is a non-pathogenic, originally dairy-derived bacterium with strong antimicrobial activity against other Gram-positive bacteria, such as other enterococci and clostridia19,20. It is possible that this organism, which utilises lactose and galactose19, can opportunistically take advantage of the available niche in the infant gut when the abundance of normally dominant bacteria is low and successfully outcompete other similar bacteria. Instead of enterococci, Lewis et al. discovered an increased abundance of streptococci, also belonging to the class Lactobacillales, in the infants of non-secretor mothers15, while Underwood et al. report a reduced abundance of Lactobacillales in premature infants of non-secretor mothers21. Most lactobacilli do not degrade complex HMOs22, so the latter result is likely due to indirect effects of the HMOs on other bacteria.
In infants of non-secretor mothers there seems to be a trend towards increased abundance of enterobacteria15,21, which we also observed in the caesarean born infants. Many members of enterobacteria are inflammatory, some even pathogenic. Fucosylated oligosaccharides are decoy receptors for many pathogenic bacteria, including members of enterobacteria; hence, they have a potential to reduce their adhesion to the gut, thus protecting the infant23,24,25. In addition, fucosylated HMOs bind enterotoxin produced by E. coli and inhibit its effects on intestinal cells26, and reduce LPS-induced inflammation in gut epithelium8. Fucosylated HMOs may thus reduce the colonisation ability of enterobacteria as well as their inflammatory effects in the infant gut, particularly among prematurely born infants.
A novel finding in our study was the increased abundance of Akkermansia in the caesarean-born infants of secretor mothers. Akkermansia muciniphila is able to degrade HMOs27, and thus may benefit from the presence of 2′FL in the situation in caesarean-born infants where normally abundant HMO-degrading members of the community, bifidobacteria and bacteroides, are depleted. Akkermansia strengthens the gut barrier and likely contributes positively to infant gut health28.
Low total abundance of bifidobacteria, and low abundance of typical infant-type bifidobacteria, in infancy has been associated with allergic disease29,30,31, which may explain the observed associations between maternal secretor status and infant allergy risk3,4. Several bifidobacterial strains have immunomodulatory effects32,33,34,35,36. Consequently, supplementation with bifidobacteria has been shown to reduce the incidence of allergic diseases in infants37.
Our results show that caesarean birth may be especially detrimental to the microbiota of infants fed by non-secretor mothers, potentially leading to increased risk of allergic diseases3,4. Screening for FUT2 genotype or 2′FL in the breast milk of mothers giving birth by caesarean section would allow these at-risk infants to be identified and treated. These infants would most likely benefit from specific interventions, such as supplementation with bifidobacteria, bifidogenic 2′fucosylated HMOs like 2′FL, or other compounds that could be effective in reducing their allergy incidence.
We collected breast milk samples on postpartum day 3 and infant faecal samples at age 3 months during a probiotic intervention trial38. The study was approved by the medical ethical board of Helsinki and Uusimaa Hospital District, Finland and was conducted according to the Declaration of Helsinki. Parents provided written informed consent. For this study, we selected a subset of the original cohort with the following criteria: both samples available, infant breastfed (exclusively or partially) at the time of faecal sample collection, placebo treatment during the trial (no probiotic given to infant or mother), and no antibiotics given to the infant prior to faecal sample collection. In total we included 76 infants of secretor mothers (58 vaginally born, 62% fully breastfed, and 18 caesarean born, 33% fully breastfed) and 15 infants of non-secretor mothers (10 vaginally born, 70% fully breastfed, and 5 caesarean born, 67% fully breastfed).
Breast milk samples were assigned to a group (i) with FUT2 dependent milk oligosaccharides (FUT2 positive) and (ii) without FUT2 dependent milk oligosaccharides (FUT2 negative) using 2 independent methods, as described earlier3,39. Briefly, skimmed breast milk samples were analysed using MALDI-TOF (matrix assisted laser desorption/ionization - time of flight) mass spectrometry (MS) profiling and liquid chromatography to quantify 2′fucosyllactose (2′FL) and by high performance anion exchange chromatography (HPAEC) with a CarboPac PA1 analytical column coupled to a pulsed amperometry detector (ICS3000, Thermo Fischer Dionex, Sunnyvale, USA). The distribution of 2′FL values was close to normal. The mean ± sd level of 2′FL in the milk of secretor mothers was 5664 ± 2048 mg/l (vaginal birth) and 3810 ± 1183 mg/l (Caesarean birth). The amount was significantly lower in the Caesarean group (ANOVA, p = 0.0003). The mean amount in the milk of non-secretor mothers was below 50 mg/l.
Faecal samples were analysed for microbiota composition by 16S rRNA amplicon sequencing. DNA was extracted from the faecal samples using a repeated bead-beating protocol40. The library preparation was performed essentially according to the protocol by Illumina, except that the 16S rRNA gene amplification and barcoding was performed in a single reaction. The PCR reaction comprised 1 ng/μl template, 1X Phusion® Master Mix (ThermoFisher, catalog number: F-531L), 0.25 μM V3-V4 locus specific primers and 0.375 μM TruSeq dual-index primers. The PCR was run under the following settings: 98 °C for 30 s, 27 cycles of 98 °C for 10 s, 62 °C for 30 s, 72 °C for 15 s and finally 10 min at 72 °C, where after the samples were stored at 4 °C. The PCR clean-up was performed with AMPure XP beads (Beckman Coulter, Copenhagen, Denmark) and confirmation of the correct amplicon size (ca. ~640 base pairs) was performed on a Bioanalyzer DNA 1000 chip (Agilent Technology, Santa Clara, CA, USA). The pooled libraries were sequenced with an Illumina MiSeq or HiSeq2500 in Rapid Run mode. The median number of reads obtained per sample was 46 260 (range 4260-137 400). The samples were randomly assigned to the different sequencing platforms. To make sure the results don’t suffer from technical bias, we sequenced three artificial communities of known composition on both platforms and compared the results (Supplementary Fig. 1). No systematic difference was observed between the different sequencing platforms. The sequencing platform did not explain a significant amount of variation in the real data (p = 0.3, multivariate permutational anova).
Statistical analysis was conducted in R, using the package mare41, with tools from packages vegan42, MASS43, and nlme44. Although paired-end sequencing was conducted, we only used the forward reads truncated to 150 bases, as we have observed using artificial communities of known composition that longer reads provide unreliable results45. Taxonomic annotation was performed using USEARCH46 by mapping the reads to the SILVA 16S rRNA reference database version 11547, restricted to gut-associated taxa (available through the R package mare41). We did not rarefy the data, but instead used the number of reads per sample as the offset in the models. We adjusted for full or partial breastfeeding in the models. Due to multiple testing, we considered FDR-corrected p < 0.1 as significant, but report uncorrected p-values in the text for clarity. Both corrected and uncorrected p-values are presented in Supplementary Table 1. For reliable results, it is extremely important that the data follow the underlying assumptions of the statistical test (particularly independence and normal distribution of residuals). The R-package mare addresses this issue by iteratively finding the most suitable model for each taxon. For this reason, the statistical test is not the same for all taxa, as the distribution of the data varies between taxa. Very commonly, there are patterns in the residuals that must be adjusted for. In these cases, generalised least squares models are used that allow for the residual variation to be modelled separately.
The DNA sequencing data are available at ENA (http://www.ebi.ac.uk/ena) under the accession number PRJEB27325.
Kunz, C. et al. Influence of Gestational Age, Secretor, and Lewis Blood Group Status on the Oligosaccharide Content of Human Milk. J. Pediatr. Gastroenterol. Nutr. 64, 789–798 (2017).
Totten, S. M. et al. Comprehensive profiles of human milk oligosaccharides yield highly sensitive and specific markers for determining secretor status in lactating mothers. Journal of proteome research 11, 6124–6133 (2012).
Sprenger, N. et al. FUT2-dependent breast milk oligosaccharides and allergy at 2 and 5 years of age in infants with high hereditary allergy risk. Eur. J. Nutr. 56, 1293–1301 (2017).
Seppo, A. E., Autran, C. A., Bode, L. & Jarvinen, K. M. Human milk oligosaccharides and development of cow’s milk allergy in infants. J. Allergy Clin. Immunol. 139, 708–711.e5 (2017).
Eiwegger, T. et al. Human milk–derived oligosaccharides and plant-derived oligosaccharides stimulate cytokine production of cord blood T-cells in vitro. Pediatr. Res. 56, 536 (2004).
Eiwegger, T. et al. Prebiotic oligosaccharides: in vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties. Pediatric Allergy and Immunology 21, 1179–1188 (2010).
Noll, A. J. et al. Human DC-SIGN binds specific human milk glycans. Biochem. J. 473, 1343–1353 (2016).
He, Y. et al. The human milk oligosaccharide 2′-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation. Gut 65, 33–46 (2016).
Katayama, T. et al. Molecular cloning and characterization of Bifidobacterium bifidum 1,2-alpha-L-fucosidase (AfcA), a novel inverting glycosidase (glycoside hydrolase family 95). J. Bacteriol. 186, 4885–4893 (2004).
Marcobal, A. et al. Bacteroides in the Infant Gut Consume Milk Oligosaccharides via Mucus-Utilization Pathways. Cell Host & Microbe 10, 507–514 (2011).
Sela, D. A. et al. Bifidobacterium longum subsp. infantis ATCC 15697 alpha-fucosidases are active on fucosylated human milk oligosaccharides. Appl. Environ. Microbiol. 78, 795–803 (2012).
Ruiz-Moyano, S. et al. Variation in consumption of human milk oligosaccharides by infant gut-associated strains of Bifidobacterium breve. Appl. Environ. Microbiol. 79, 6040–6049 (2013).
Yu, Z., Chen, C. & Newburg, D. S. Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes. Glycobiology 23, 1281–1292 (2013).
Bäckhed, F. et al. Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. Cell host & microbe 17, 690–703 (2015).
Lewis, Z. T. et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome 3, 13 (2015).
Wang, M. et al. Fecal microbiota composition of breast-fed infants is correlated with human milk oligosaccharides consumed. J. Pediatr. Gastroenterol. Nutr. 60, 825–833 (2015).
Asakuma, S. et al. Physiology of consumption of human milk oligosaccharides by infant gut-associated bifidobacteria. J. Biol. Chem. 286, 34583–34592 (2011).
Sela, D. A. Bifidobacterial utilization of human milk oligosaccharides. Int. J. Food Microbiol. 149, 58–64 (2011).
Morandi, S., Cremonesi, P., Povolo, M. & Brasca, M. Enterococcus lactis sp. nov., from Italian raw milk cheeses. Int. J. Syst. Evol. Microbiol. 62, 1992–1996 (2012).
Morandi, S., Silvetti, T. & Brasca, M. Biotechnological and safety characterization of Enterococcus lactis, a recently described species of dairy origin. Antonie Van Leeuwenhoek 103, 239–249 (2013).
Underwood, M. A. et al. Human milk oligosaccharides in premature infants: absorption, excretion, and influence on the intestinal microbiota. Pediatr. Res. 78, 670 (2015).
Schwab, C. & Gänzle, M. Lactic acid bacteria fermentation of human milk oligosaccharide components, human milk oligosaccharides and galactooligosaccharides. FEMS Microbiol. Lett. 315, 141–148 (2011).
Newburg, D. S. et al. Innate protection conferred by fucosylated oligosaccharides of human milk against diarrhea in breastfed infants. Glycobiology 14, 253–263 (2003).
Ruiz-Palacios, G. M., Cervantes, L. E., Ramos, P., Chavez-Munguia, B. & Newburg, D. S. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J. Biol. Chem. 278, 14112–14120 (2003).
Morrow, A. L. et al. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J. Pediatr. 145, 297–303 (2004).
Crane, J. K., Azar, S. S., Stam, A. & Newburg, D. S. Oligosaccharides from human milk block binding and activity of the Escherichia coli heat-stable enterotoxin (STa) in T84 intestinal cells. J. Nutr. 124, 2358–2364 (1994).
Ottman, N. Host immunostimulation and substrate utilization of the gut symbiont Akkermansia muciniphila. PhD thesis. Wagenigen University (2015).
Derrien, M., Belzer, C. & de Vos, W. M. Akkermansia muciniphila and its role in regulating host functions. Microb. Pathog. 106, 171–181 (2017).
Björkstén, B., Sepp, E., Julge, K., Voor, T. & Mikelsaar, M. Allergy development and the intestinal microflora during the first year of life. J. Allergy Clin. Immunol. 108, 516–520 (2001).
He, F. et al. Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol. Med. Microbiol. 30, 43–47 (2001).
Kalliomäki, M. et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J. Allergy Clin. Immunol. 107, 129–134 (2001).
Lammers, K. M. et al. Immunomodulatory effects of probiotic bacteriaDNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunology & Medical Microbiology 38, 165–172 (2003).
Helwig, U. et al. Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J. Gastroenterol. 12, 5978–5986 (2006).
Li, N. et al. Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomy-fed infant rats. Pediatr. Res. 66, 203–207 (2009).
López, P., Gueimonde, M., Margolles, A. & Suárez, A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int. J. Food Microbiol. 138, 157–165 (2010).
Jeon, S. G. et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 8, e1002714 (2012).
Kim, J. Y. et al. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double‐blind, randomized, placebo‐controlled trial. Pediatric Allergy and Immunology 21 (2010).
Kuitunen, M., Kukkonen, A. K. & Savilahti, E. Impact of Maternal Allergy and Use of Probiotics during Pregnancy on Breast Milk Cytokines and Food Antibodies and Development of Allergy in Children until 5 Years. Int. Arch. Allergy Immunol. 159, 162–170 (2012).
Blank, D. et al. High-throughput mass finger printing and Lewis blood group assignment of human milk oligosaccharides. Anal Bioanal Chem 401, 2495–2510 (2011).
Salonen, A. et al. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: Effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J. Microbiol. Methods 81, 127–134 (2010).
Korpela, K. mare: Microbiota Analysis in R Easily. R package version 1.0. (2016).
Oksanen, J. et al. vegan: Community Ecology Package. R package version 2, 0–6 (2013).
Venables, W. & Ripley, B. In Modern Applied Statistics with S (Springer, New York, 2002).
Pinheiro, J., Bates, D., DebRoy, S. & Sarkar, D. The R Development Core Team. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3, 1–108 (2013).
Korpela, K. et al. Intestinal microbiota development and gestational age in preterm neonates. Scientific reports 8, 2453 (2018).
Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010).
Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590–D596 (2012).
The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Korpela, K., Salonen, A., Hickman, B. et al. Fucosylated oligosaccharides in mother’s milk alleviate the effects of caesarean birth on infant gut microbiota. Sci Rep 8, 13757 (2018). https://doi.org/10.1038/s41598-018-32037-6
- Cesarean Birth
- Human Milk Oligosaccharides (HMOs)
- Secretor Mothers
- Maternal Secretions
- Birth Mode
A potentially probiotic strain of Enterococcus faecalis from human milk that is avirulent, antibiotic sensitive, and nonbreaching of the gut barrier
Archives of Microbiology (2022)
Pediatric Research (2021)
ISME Communications (2021)
Activation of the G-protein coupled receptor GPR35 by human milk oligosaccharides through different pathways
Scientific Reports (2020)
Akkermansia muciniphila uses human milk oligosaccharides to thrive in the early life conditions in vitro
Scientific Reports (2020)